EAU 2025 | Urine-based tool predicts immunotherapy response in bladder cancer
Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, describes the development of BlaDimiRplus, a novel urine-based method to predict response to bacillus Calmette-Guérin (BCG) immunotherapy in non-muscle-invasive bladder cancer (NMBIC). This strategy integrates miRNA and cytokine profiling to identify likely responders before treatment. Data from a BCG-treated cohort showed strong predictive performance for select biomarkers, with improved accuracy when combined. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
